WO1988006619A1 - Preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals - Google Patents

Preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals Download PDF

Info

Publication number
WO1988006619A1
WO1988006619A1 PCT/SU1987/000024 SU8700024W WO8806619A1 WO 1988006619 A1 WO1988006619 A1 WO 1988006619A1 SU 8700024 W SU8700024 W SU 8700024W WO 8806619 A1 WO8806619 A1 WO 8806619A1
Authority
WO
WIPO (PCT)
Prior art keywords
biomass
treatment
tsmpm
tsμpμ
shτamma
Prior art date
Application number
PCT/SU1987/000024
Other languages
French (fr)
Russian (ru)
Inventor
Valery Veniaminovich Smirnov
Svetlana Nikolaevna Kharchenko
Semen Rafailovich Reznik
Vladimir Petrovich Litvin
Valentina Alexeevna Vjunitskaya
Original Assignee
Institut Mikrobiologii I Virusologii Imeni D.K.Zab
Ukrainskaya Selskokhozyaistvennaya Akademia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Mikrobiologii I Virusologii Imeni D.K.Zab, Ukrainskaya Selskokhozyaistvennaya Akademia filed Critical Institut Mikrobiologii I Virusologii Imeni D.K.Zab
Priority to JP62502918A priority Critical patent/JPH01502340A/en
Priority to PCT/SU1987/000024 priority patent/WO1988006619A1/en
Priority to DE873790919T priority patent/DE3790919T1/en
Priority to CH4117/88A priority patent/CH674149A5/de
Publication of WO1988006619A1 publication Critical patent/WO1988006619A1/en
Priority to GB8823554A priority patent/GB2209343B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus

Definitions

  • ⁇ e ⁇ ⁇ e ⁇ i ⁇ d of ⁇ uzhayuschey s ⁇ edy (from v ⁇ zdu ⁇ a, ⁇ edme ⁇ v u ⁇ da, ⁇ b ⁇ lny ⁇ zhiv ⁇ ny ⁇ , ⁇ ⁇ e ⁇ s ⁇ nala and d ⁇ ugi ⁇ is ⁇ chni ⁇ v) in ⁇ ganizm zhiv ⁇ ny ⁇ m ⁇ gu ⁇ ⁇ ada ⁇ ⁇ azlichnye ⁇ a ⁇ gennye and usl ⁇ vn ⁇ ⁇ a ⁇ gennye mi ⁇ ganizmy (en ⁇ e ⁇ a ⁇ gennye ⁇ ishechnye ⁇ al ⁇ ch ⁇ i, s ⁇ a- ⁇ il ⁇ i, ⁇ ei, ⁇ lebsielly 'and salm ⁇ nell
  • the drugs are more effective for the treatment and treatment of gastrointestinal diseases of the living from vascular microculture.
  • Eti ⁇ réelle -2- Injuries are at risk of physical injury to the stomach and the stomach, which is associated with gastrointestinal disease, ⁇ réelle ⁇ , for example ⁇ ,
  • the indications indicated include one type of microorganism that does not provide a wide range of its antagonistic features.
  • the basic task of the invention was to alter the biomass of bacteria and use new strains of microbial diseases to treat medications for the treatment of patients
  • the quick link is desirable with a dry link.
  • the culture produces glucose, arabinosis, beckoning, and the formation of an acid without gas.
  • the operation of Facebook - Positive is positive.
  • the culture does not produce gas from ⁇ 0 3 under anaerobic conditions; it does not produce arginine dihydrogenase.
  • the crop grows in a environment that contains 7% of ya
  • a meat and poultry bouillon is used to produce a small-film, sometimes with an extra-thick film.
  • the culture is exploring catalase.
  • the product is available on the market.
  • the inventive product provides a pure, crystallized dry mass of light and non-volatile light that is not consumable to us.
  • the bulk for water is not more than 5%.
  • the product is emitted in glass ampoules with a content of 250 mg of dry substance (300-400 milliliters of microcells) or in glass flasks with a content of 500 mg (600 mg).
  • the claimed ⁇ e ⁇ a ⁇ a ⁇ m ⁇ zhe ⁇ by ⁇ is ⁇ lz ⁇ van in ⁇ aches ⁇ ve s ⁇ eds ⁇ va ⁇ ila ⁇ i ⁇ i or ⁇ aches ⁇ ve s ⁇ eds ⁇ va treatment ⁇ s ⁇ y ⁇ zhelud ⁇ chn ⁇ - ⁇ ishechny ⁇ zab ⁇ levany m ⁇ l ⁇ dnya ⁇ a sels ⁇ - ⁇ zyays ⁇ venny ⁇ zhiv ⁇ ny ⁇ (disba ⁇ e ⁇ i ⁇ za, ⁇ liba ⁇ e ⁇ i ⁇ za, salm ⁇ nelleza, ⁇ azlichny ⁇ d ⁇ ugi ⁇ ⁇ s ⁇ y ⁇ zhelud ⁇ chn ⁇ - ⁇ ishechny ⁇ zab ⁇ levany sels ⁇ zyays venny ⁇ zhiv ⁇ ny ⁇ , vyzvanny ⁇ ⁇ a- ⁇ gennymi and usl ⁇ vn ⁇ pathogenic microorganisms).
  • test results of the claimed product showed that out of 328 newborn calves, which were purchased by the claimed device, 19 of them had any injuries. ⁇ live group of 185 live
  • the claimed medication was changed to 284 calves with various gastrointestinal diseases
  • the inventive process was designated as the next one.
  • Compound ampoules 300-400 milligrams of micro-cells were mixed in one milk or water, they were cooled and cooled to 25–30 ° C, and they were allowed to cool.
  • the claimed preparation showed a high therapeutic and preventive effect.
  • the product is characterized by a high rate of antagonism to the static response to various types of microorganisms - pathogens.
  • the product helps to increase the protective reactions of the organism of animals (induction of the endogenous interactions,
  • the claimed process is as follows.
  • ⁇ Brass As a filling medium, use a mixture of a quick-release mixture of quick-release or gelatin with sugar or glucose. The resulting mixture is poured into a stylish ampoule 1 and placed in a corner, a cracker for 24 hours at a temperature not exceeding -20 ° C. The product is licensed for at least 44 hours and operating at -20 ° to + 20 ° ⁇ . After filizirovaniya ampoules solder. The inventive preparation keeps the activity and the duration of the storage for at least 2 years.
  • the test for harmlessness leads to the following test: when administered directly, at least 5 mice weighing 18-22 grams are much more lively than the mouse, but the weight is very good. on the fifth day of observation.
  • the conversion of speci fi c activity is carried out by the following process. Researches the antagonistic properties of -10- sections of microcultures included in the composition of the drug, in addition to testing, the number of tests carried out by the Party is limited,
  • test results are presented in the table. For example, 2.
  • the inventive product is of the following composition, in% (%): biomass strain . ⁇ . ⁇ admir ⁇ transaction ⁇ ⁇ ⁇ £ ⁇ -2336 20 35 5th gelatin solution. 21 sugar 4 -II-

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals comprises a biomass of strain Bacillus subtilis TsMPM No. B-2335 and a biomass of strain Bacillus licheniformis TsMPM No. B-2336 produced from wild cultures by way of natural selection according to depending characteristics of their maximum and stable antagonistic activity in the course of their cultivation on artificial nutritive media deposited at the Central Museum of Industrial Microorganisms of the USSR Research Institute for Genetics and Industrial Microorganism Breeding, and further comprises a filler in the following ratio of initial components in per cent by weight: biomass of strain Bacillus subtilis TsMPM No. B-2335, containing 150-200 billion microbe cells in 1 ml3 45-60, biomass of strain Bacillus licheniformis TsMPM No. B-2336, containing 150-200 billion microbe cells in 1 ml3 15-20, filler the balance.

Description

ПΡΕПΑΡΑΤ ДΚЯ ПΡΟΦШГΑΚΤИΚИ И ЛΕЧΕΗИЯ ЖΕЛ7ДΟЧΗΟ- ПΡΕПΑΡΑΤ ДΚЯ ПΡΟФШГΑΚΤИΚИ AND ЛУЧΕΗИЯ ЖΕЛ7ДΟЧΗΟ-
ΚИШΕЧΗЫΧ ЗΑБШГΕΒΑΗИЙ СΕЛЬСΚΟΧΟЗЯЙСΤΒΕΗΗЫΧΚISHΕCHΗYΧ ZΑBSHGΕΒΑΗY SΕLSΚΟΧΟZYЙSΤΒΕΗΗYΧ
ЖИΒΟΤШΧLIFE
Οбласτь τеχниκи Ηасτοящее изοбρеτение οτнοсиτся κ веτеρинаρии, а το нее , κ πρеπаρаτу для προφилаκτиκи и лечения ж'елудοчнο- κишечныχ забοлеваний сельсκοχοзяйсτвенныχ живοτныχ.Οblasτ τeχniκi Ηasτοyaschee izοbρeτenie οτnοsiτsya K veτeρinaρii and το it, K πρeπaρaτu for προφilaκτiκi and treatment x 'eludοchnο- κishechnyχ zabοlevany selsκοχοzyaysτvennyχ zhivοτny χ.
Пρедшесτвующий уροвенъ τеχниκиPREVIOUS TECHNOLOGY
Β сοвρеменныχ живοτнοвοдчесκиχ κοмπлеκсаχ, где κοн- ценτρиρуеτся значиτельнοе κοличесτвο мοлοдняκа селъсκο- χοзяйсτвенныχ живοτныχ, даже πρи сοблюдении удοвлеτвορи τельныχ гигиеничесκиχ услοвий, у значиτельнοй часτи нο- вοροжденныχ вοзниκаюτ οсτρые желудοчнο-κишечные забοле-Β sοvρemennyχ zhivοτnοvοdchesκiχ κοmπleκsaχ where κοn- tsenτρiρueτsya znachiτelnοe κοlichesτvο mοlοdnyaκa selsκο- χοzyaysτvennyχ zhivοτnyχ even πρi sοblyudenii udοvleτvορi τelnyχ gigienichesκiχ uslοvy have znachiτelnοy chasτi nο- vοροzhdennyχ vοzniκayuτ οsτρye zheludοchnο-κishechnye zabοle-
• вания. Οснοвные πρичины τаκиχ забοлеваний сοсτοяτ в τοм, чτ в πеρвые часы и дни ποсле ροждения у живοτныχ еще не сφορмиροвана нορмальная миκροφлορа, игρающая важную ροлъ προτивοинφеκциοннοй защиτы . Β эτοτ πеρиοд из οκρужающей сρеды (из вοздуχа, πρедмеτοв уχοда, οτ бοльныχ живοτныχ, οτ πеρсοнала и дρугиχ исτοчниκοв ) в ορганизм живοτныχ мοгуτ ποπадаτь ρазличные πаτοгенные и услοвнο πаτοгенные миκροορганизмы ( энτеροπаτοгенные κишечные πалοчκи, сτа- φилοκοκκи, προτеи,κлебсиеллы, 'сальмοнеллы и дρ. ) , κοτο- ρые πρаκτичесκи бесπρеπяτс веннο ρазмнοжаюτся в κишечни- κе нοвοροжденныχ, вызывая у ниχ желудοчнο-κишечные забο- левания ρазличнοй τяжесτи. Ρазвиτие τаκиχ забοлеваний в ρаннем вοзρасτе πρивοдиτ κ οслаблению нοвοροжденныχ и снижению προценτа иχ сοχρаннοсτи (гибели часτи живοτныχ) Шиροκο извесτнο πρименение для лечения οсτρыχ желу- дοчнο-κишечныχ забοлеваний анτибиοτиκοв , сульφаιлидныχ и ниτροφуρанοвыχ πρеπаρаτοв , а τаκже οτваροв τρав и дρугиχ сρедсτв . Οднаκο , все эτи сρедсτва недοсτаτοчнο эφφеκτивн τаκ κаκ ρяд πаτοгенныχ и услοвнο πаτοгенныχ миκροορганиз мοв усτοйчивы κ эτим сρедсτвам. Β насτοящее вρемя бοлее πеρсπеκτивными являюτся πρе- πаρаτы для προφилаκτиκи и лечения желудοчнο-κишечныχ за- бοлеваний живοτныχ из живыχ миκροбныχ κульτуρ . Эτи πρе -2- πаρаτы сποсοбсτвуюτ исκуссτвеннοму φορмиροванию на ρан- нем πеρиοде жизни живοτныχ в иχ желудοчнο-κишечнοм τρаκτе миκροφяορы, сποсοбнοй ποдавиτь ρазмнοжение в нём πаτοген- ныχ и услοвнο πаτοгенныχ миκροορганизмοв . Τаκ, наπρимеρ,• vania. The main causes of such diseases are found to be that in the first hours and days after birth in animals, a normal disease, which plays an important role, is not affected. Β eτοτ πeρiοd of οκρuzhayuschey sρedy (from vοzduχa, πρedmeτοv uχοda, οτ bοlnyχ zhivοτnyχ, οτ πeρsοnala and dρugiχ isτοchniκοv) in ορganizm zhivοτnyχ mοguτ ποπadaτ ρazlichnye πaτοgennye and uslοvnο πaτοgennye miκροορganizmy (enτeροπaτοgennye κishechnye πalοchκi, sτa- φilοκοκκi, προτei, κlebsielly 'and salmοnelly etc.), which are generally impaired by the vein, are introduced into the intestinal tract, causing gastrointestinal distress in them. Ρazviτie τaκiχ zabοlevany in ρannem vοzρasτe πρivοdiτ κ οslableniyu nοvοροzhdennyχ and reduce προtsenτa iχ sοχρannοsτi (destruction chasτi zhivοτnyχ) Shiροκο izvesτnο πρimenenie for treating οsτρyχ zhelu- dοchnο-κishechnyχ zabοlevany anτibiοτiκοv, and sulφaιlidnyχ niτροφuρanοvyχ πρeπaρaτοv and τaκzhe οτvaροv τρav and dρugiχ sρedsτv. However, all of these components are not sufficiently effective, as there are a number of pathogenic and conditionally harmful microorganisms that are stable to this medium. Β At present, the drugs are more effective for the treatment and treatment of gastrointestinal diseases of the living from vascular microculture. Eti πρе -2- Injuries are at risk of physical injury to the stomach and the stomach, which is associated with gastrointestinal disease, Τаκ, for example πρ,
5 извесτен πρеπаρаτ из живыχ κульτуρ миκροορганизма зϊггеρ-Ьο сοссϊш Гаесϊит Сегήаϊϊе 68 (πаτенτ Βелиκθбρиτании £ 1300446).5 the product was known from the live culture of the microorganism of the South Caucasus, Gaessit Segres 68 (patent price £ 1300446).
Уκазанныδ πρеπаρаτ вκлючаеτ οдин вид миκροορганизма, чτο не οбесπечиваеτ шиροκοгο сπеκτρа егο анτагοнисτиче-The indications indicated include one type of microorganism that does not provide a wide range of its antagonistic features.
10 сκοгο дейсτвия. Κροме τοгο, уκазанныЁ πρеπаρаτ не οκазы- ваеτ сτимулиρующегο влияния на защиτные ρеаκции ορганиз- ма живοτныχ (не индуциρуеτ эндοгенный инτеρφеροн, не πο- вышаеτ φагοциτаρную аκτивнοсτь лейκοциτοв κροви), чτο τаκже οгρаничиваеτ οбласτь егο πρименения.10 good actions. Κροme τοgο, uκazannyO πρeπaρaτ not οκazy- vaeτ sτimuliρuyuschegο impact on zaschiτnye ρeaκtsii ορganiz- ma zhivοτnyχ (not indutsiρueτ endοgenny inτeρφeροn not πο- vyshaeτ φagοtsiτaρnuyu aκτivnοsτ leyκοtsiτοv κροvi) chτο τaκzhe οgρanichivaeτ οblasτ egο πρimeneniya.
15 Ρасκρыτие изοбρеτения15 DISCLOSURE OF THE INVENTION
Β οснοву изοбρеτения ποлοжена задача πуτем изменения биοмассы баκτеρий и πρименения нοвыχ шτаммοв миκροορга- низмοв ποлучиτь πρеπаρаτ для προφилаκτиκи и лечения же- лудοчнο-κишечныχ забοлеваний сельсκοχοзяйсτвенныχ живοτ-The basic task of the invention was to alter the biomass of bacteria and use new strains of microbial diseases to treat medications for the treatment of patients
20 ныχ, οбладающий высοκοй эφφеκτивнοсτью дейсτвия, χаρаκ- τеρизующийся шиροκим сπеκτροм дейсτвия πο ποдавлению ροс- τа πаτοгенныχ и услοвнο πаτοгенныχ миκροορганизмοв , сτи- мулиρующий защиτные ρеаκции ορганизма живοτнοгο, не вызы- вающий οслοжнений, не οκазывающии ποбοчнοгο дейсτвия,20 nyχ, οbladayuschy vysοκοy eφφeκτivnοsτyu deysτviya, χaρaκ- τeρizuyuschiysya shiροκim sπeκτροm deysτviya πο ποdavleniyu ροs- τa πaτοgennyχ and uslοvnο πaτοgennyχ miκροορganizmοv, sτi- muliρuyuschy zaschiτnye ρeaκtsii ορganizma zhivοτnοgο not rotate and causes οslοzhneny not οκazyvayuschii ποbοchnοgο deysτviya,
25 лροсτοй в πρименении, ποдлежащий длиτельнοму χρанению. Задача ρешена τем, чτο заявляемый πρеπаρаτ для προ- φилаκτиκи и лечения желудοчнο-κишечныχ забοлеваний сель- сκοχοзяйсτвенныχ живοτныχ, вκлючаюший биοмассу баκτеρий, сοгласнο изοбρеτению, в κачесτве биοмассы баκτеρий сс—25 easy to use, long-term storage. The problem was solved in that the claimed medication for the treatment of gastrointestinal diseases and gastrointestinal diseases, including the occurrence of a biomass, was reported.
30 деρжиτ биοмассу шτамма Βасϋϊиа зиЪ-Ыϋз ЦΜГΜ Β-2335 и биοмассу шτамма Βасϋϊиз ΙΙс-αеηΙ-ГοгтΙэ ЦΜПΜ & Β-2336, селеκциοниροванныχ из диκиχ κульτуρ πуτем есτесτвеннοгο οτбορа πο πρизнаκам наибοльшей и сτабильнοй анτагοнис- τичесκοй аκτивнοсτи πρи κульτивиροвании на исκуссτвенныχ30 deρzhiτ biοmassu shτamma Βasϋϊia zi-Yϋz TSΜGΜ Β-2335 and biοmassu shτamma Βasϋϊiz ΙΙs-αe η Ι-GοgtΙe TSΜPΜ & Β-2336 seleκtsiοniροvannyχ of diκiχ κulτuρ πuτem esτesτvennοgο οτbορa πο πρiznaκam naibοlshey and sτabilnοy anτagοnis- τichesκοy aκτivnοsτi πρi κulτiviροvanii on isκussτvennyχ
35 πиτаτельныχ сρедаχ, деποниροванныχ в Ценτρальнοм музее πρσмышленныχ миκροορганизмοв Βсесοюзнοгο научнο-исследο- -3- ваτельсκοгο инсτиτуτа генеτиκи и селеκции προмышленныχ миκροορганизмοв , и сοдеρжиτ наποлниτель πρи следующем сοοτнοшении исχοдныχ κοмποненτοв в шο .% : биοмасса шτамма Βасϋϊиз 5 зиЪΙ-ΙПз ЦΜПΜ Л Β-2335, сοдеρжащая 150-200 млρц миκροбныχ κлеτοκ в I мл, 45-60 биοмасса шτамма Βасιϊϊиз35 healthy χ environment χ , located in the Central Museum are industrial χ of the microorganisms of the All-Union Scientific Research -3- vaτelsκοgο insτiτuτa geneτiκi and seleκtsii προmyshlennyχ miκροορganizmοv and sοdeρzhiτ naποlniτel πρi following sοοτnοshenii isχοdnyχ κοmποnenτοv in shο.%: Biοmassa shτamma Βasϋϊiz 5-ziΙ ΙPz TSΜPΜ A Β-2335, 150-200 sοdeρzhaschaya mlρts miκροbnyχ κleτοκ in I mL, 45 60 Biomass Stamma Βасιϊϊiz
ΙϊсЪеηϊϊ'οгтϊз ЦΜПΜ £ Β-2336, Ю сοдеρжащая 150-200 млρд миκροбныχ κлеτοκ в I мл, 15-20 наποлниτель οс τаль нοе .Ъсъеηϊϊ'огтϊз ЦΜПΜ £ Β-2336, containing 150-200 mld of micro cells in I ml, 15-20 filler with a new one.
Эφφеκτивнοсτь дейсτвия заявляемοгο πρеπаρаτа οбесπе- чиваеτся исποльзοванием уκазанныχ шτаммοв . 15 Шτамм Βасϊϊϊив зиЪ-Ыϋз ЦΜПΜ Β-2335 χаρаκτеρизуеτ- ся свοйсτвοм οπρеделеннοе вρемя сοχρаняτъся в ρазличныχ οτделаχ πищеваρиτельнοгο τρаκτа живοτныχ, οбладаеτ анτа- гοнисτичесκим дейсτвием πο οτнοшению κ πаτοгенным и ус- ЛΟΒΗΟ πаτοгенным баκτеρиям (Ρзеиάοтοηаз
Figure imgf000005_0001
5Ъ±§е 2(л зοηηеϊ Заϊтοηеϊϊа Ιезϊасο , Заϊтοηеϊϊа -ЬуρЪ.ϊтиг1ит, Заϊтοη зχ-еηϊеу , Заϊтοηеϊϊа ηетсροгχ- , ΚΙеЪзχеΙΙа ρηеитο'ηϊае Ρгο"Ьеи гχзи дρугие) , сτимулиρуеτ φагοциτаρную аκτивнοсτь лейκοци- τοв κροви, ποвышаеτ индуκцию эндοгеннοгο инτеρφеροна в ορганизме живοτныχ, не влияеτ на нορмальную миκροφлορу .The effectiveness of the claimed product is ensured by the use of the above-mentioned stamps. 15-zi Shτamm Βasϊϊϊiv Yϋz TSΜPΜ Β-2335 χaρaκτeρizueτ- Xia svοysτvοm οπρedelennοe vρemya sοχρanyaτsya in ρazlichnyχ οτdelaχ πischevaρiτelnοgο τρaκτa zhivοτnyχ, οbladaeτ anτa- gοnisτichesκim deysτviem πο οτnοsheniyu κ πaτοgennym and INSTALLS LΟΒΗΟ πaτοgennym baκτeρiyam (Ρzeiάοtοηaz
Figure imgf000005_0001
Ge 5 ± 2 (n zοηηeϊ Zaϊtοηeϊϊa Ιezϊasο, Zaϊtοηeϊϊa -uρ.ϊtig1it, Zaϊtο η zχ-eηϊeu, Zaϊtοηeϊϊa ηetsροgχ-, ΚΙezχeΙΙa ρηeitο 'ηϊae Ρgο "Leu gχzi dρugie) sτimuliρueτ φagοtsiτaρnuyu aκτivnοsτ leyκοtsi- τοv κροvi, ποvyshaeτ induκtsiyu endοgennοgο inτeρφeροna in an organism of animals, it does not affect the normal world.
25 Шτамм Βасϋϊиз ϋсЪеηϋ'οгтΙз ЦΜПΜ & Β-2336 χаρаκτеρи- зуеτся свοйсτвοм οπρеделеннοе вρемя сοχρаняτься в ρазлич- ныχ οτделаχ πищеваρиτельнοгο τρаκτа живοτныχ, οбладаеτ анτагοнисτичесκим дейсτвием πο οτнοшению κ πаτοгенным баκτеρиям И гρибам (3-ЬаρЪуΙοсοссиз аигеиз, 3-ЬаρЪуΙοсοссиз 2^ аΙЪиз ^ Саηάϊάа аΙЪϊсаηз ^ Αзρег§ϋ1из Гϊаηеви дρугие) сτимулиρуеτ φагοциτаρную аκτивнοсτь лейκοциτοв κροви живο ныχ, не влияеτ на нορмальную миκροφлορу, χаρаκτеρизуеτся φеρменτаτивнοй аκτивнοсτью, сποсοбсτвующей προцессам πи- щеваρения. 35 в κачесτве наποлниτеля заявляемый πρеπаρаτ πρедποчτи- τельнο сοдеρжиτ смесь сывοροτκи κροви κρуπнοгο ροга- 25 Shτamm Βasϋϊiz ϋseηϋ'οgtΙz TSΜPΜ & Β-2336 χaρaκτeρi- zueτsya svοysτvοm οπρedelennοe vρemya sοχρanyaτsya in ρazlich- nyχ οτdelaχ πischevaρiτelnοgο τρaκτa zhivοτnyχ, οbladaeτ anτagοnisτichesκim deysτviem πο οτnοsheniyu κ πaτοgennym baκτeρiyam AND gρibam (3-aρuΙοsοssiz aureus, 3-aρuΙοsοssiz ^ 2 ^ aΙiz Ca άϊάa aΙϊsa η s η ^ Αzρeg§ϋ1iz Gϊaηevi dρugie) sτimuliρueτ φagοtsiτaρnuyu aκτivnοsτ leyκοtsiτοv κροvi zhivο nyχ not vliyaeτ on nορmalnuyu miκροφlορu, χaρaκτeρizueτsya φeρmenτaτivnοy aκτivnοsτyu, sποsοbsτvuyuschey προtsessam πi- schevaρeniya. 35 as a part of the filler, the claimed preparation provides a mixture of a full load of food and drink.
- 4 - τοгο сκοτа жлж желаτжна с саχаροзοй жлж глακοзοй.- 4 - Then, the quick link is desirable with a dry link.
Исжοльзοванже сывοροτκж κροвж κρуπнοгο ροгаτοгο сκοτа жлж желаτжна сποсοбсτвуеτ сτабилизации бжοлοгжчесκжχ свοжсτв κуτιьτуρ, вχοдящжχ в сοсτав πρеπаρаτа. ПρжглененжеUsually, more than once, the profit of the property is desired to stabilize the consumption of the property. Ρ ironed
5 саχаροзы жли глюκοзы οбесπечжваеτ οπτишлъные услοвжя лжοπп лжзацжж в жροцессе жзгοτοвленжя πρеπаρаτа,сοχρанения егο биοлοгжчесκжχ ж φжзжчесκжχ свοйсτв в προцессе χρаненжя ж χοροшую смешжваемοсτь с ρасτвορиτелегл жρеπаρаτа в жροцес- се егο πρименения.5 saχaροzy zhli glyuκοzy οbesπechzhvaeτ οπτishlnye uslοvzhya lzhοπp lzhzatszhzh in zhροtsesse zhzgοτοvlenzhya πρeπaρaτa, sοχρaneniya egο biοlοgzhchesκzhχ w φzhzzhchesκzhχ svοysτv in προtsesse χρanenzhya w χοροshuyu smeshzhvaemοsτ with ρasτvορiτelegl zhρeπaρaτa in zhροtsesse egο πρimeneniya.
10 Лучшиκ ваρианτ οсущесτвленжя жзοбρеτенжя10 Best Options for Livelihood
Β сοсτав заяБляемοгο жρежаρаτа вχοдиτ бжοιласса уκазан- ныχ нοвыχ шτш οв.Шτаммы Βасϋϊиз зиЪ-Ыϋз ЩПΜ & Β-2335 ж Βасϋϊиз ΙχсЪ.еηϋ'οгт±з ЩПΜ 15 Β-2336 деποнжροванκ в Ценτ- ρальнοм музее προмышленныχ мжκροορганизмοв ΒсесοюзнοгοΒ sοsτav zayaBlyaemοgο zhρezhaρaτa vχοdiτ bzhοιlassa uκazan- nyχ nοvyχ shτsh οv.Shτammy Βasϋϊiz zi-Yϋz SCHPΜ & Β-2335 w Βasϋϊiz Ιχs.eηϋ'οgt SCHPΜ of ± 15 Β-2336 deποnzhροvanκ in Tsenτ- ρalnοm museum προmyshlennyχ mzhκροορganizmοv Βsesοyuznοgο
15 научнο-жсследοваτельсκοгο жнсτжτуτа генеτжκж ж селеκции προмБШшенныχ мжκροορганжзмοв. Шτамм Βасϋϊиз зиЪτ-ϊϋз ЦЖΙ й Β-2335 выделен жз джκжχ κулъτуρ ж селешгдοнжροван в жροцессе жсследοвания егο есτесτвеннοж жзменчжвοсτж πρж κульτивжροваниж на исκуссτвенныχ πжτаτельныχ сρедаχ πуτегл15 scientific and research researches of the genealogy of the breeding of the most dangerous gens. The Strain from ZZht-ϊϋ z TsZh Β-2335 is highlighted by the jjjjkkkultuzh selashgdzheng in the process of the investigation of him to the proper operation of the
20 οτбορа ваρжанταв,χаρаκτеρизующжχся нажбοлыιгей ж в το же вρемя сτабжльнοй (на προτяженжж бοлее 50 πассаже!) анτагο- нжсτжчесκοй аκτжвнοсτью.20 options for Variety, a nice game for playing at the same time (for more than 50 farther!) Antentrically active.
Εулъτуρнο-мορшοлοгжчесκие и гажзжοлοгο-бжοχιшжчесκже οсοбеннοсτж шτамма следующже: κлеτκж πалσчκοвждκοιϊ ωορмыThe most-minor and gazzholog-bzheshihszhessbenno especially the strain is as follows:
25 в жρежаρаτе " ρаздавленная" жлж "вжсячая" κаπля жοдвжжные, гρамжοлοжжτельные, жροдуπжρуюτ κаτалазу; в аэροбныχ услο- вжяχ οбρазуеτ сπορы, κοτορые в κлеτκе ρасжοлοженн ценτρальн Κульτуρа οбжлънο ρасτеτ на οбщеунοτρеблчемыχ сρедаχ (мясο- жежτοннοм агаρе, суслο-агаρе, сρеде Гροмыκο, κаρτοωельнοм25 in the "crushed" liquefied milk "heavy" drop, burning, burnt, hungry, catalyzed; in the case of international services, it is convenient to consume the cul-
ЗС агаρе). Ηа мясο-πеπτοннοм агаρе οбρазуеτ κοлοнжи имеющие неπρавильную φορму с мορщπнисτοй маτοвοй иοвеρχнοсτыз, όе- лοгο жлж белοваτο-κρемοвοгο цвеτа с жзρезанными бесτοнча- τыми κρаямж. Κοлοнжж мοгуτ τаκже быτь κρуглыыж, гладκπг-.ιж, с блесτящеж жοвеρχнοсτъю ж ροвнымж κρаяш.Οба вжда κοлοнжжZS agar). In case of meat and poultry agaries, it will not be possible to buy pans with improper form of food with a small and dirty car, which is completely irrelevant. You can also be warm, smooth, live, brilliantly live, good and happy.
35 легκο снимаюτся с агаρа πеτлей. Яρж ροсτе на мясο-πеπτοннο бульοне κульτуρа οбρазуеτ πленκу.Β мазκаχ Ι8-часοвοй κулъτу ρы οбнаρуживаιοτся гρаιшοлοκиτельше κлеτκж πалοчκοвжднοй -5- φορмы , πρямые , ρазмеροм 2,0-2, 2x0, 7-0,85 мκм, ρасποлοжен- ные οτделънο или в виде цеποчеκ. Пρи сποροοбρазοвании κле κи не ρаздуваюτся, ποсле ροсτа на глюκοзнοм агаρе в προτο πлазме не οбнаρуживаюτся вκлючения ποли- - οκсимаслянοй35 is easily removed from the agar. Yarst grows on meat and poultry boulevard culture; produces a film. Β 8 hour meal -5- ο ο ο мы,,,, мы, 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0 2,0--5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 When used without gluing, it doesn’t swell after glucose growth in the plasma;
5 κислοτы . Κульτуρа φеρменτиρуеτ глюκοзу, аρабинοзу, маниτ, κсилοзу с οбρазοванием κислοτы без газа. Ρеаκция Φοгес- -Пροсκауэρа ποлοжиτельна. Κульτуρа не οбρазуеτ газ из Ν03 в анаэροбныχ услοвияχ, не προдуциρуеτ аρгининдигидροлазу. Κульτуρа ρасτеτ на сρеде, сοдеρжащей 7% яасι , гидροлизуеτ5 acids. The culture produces glucose, arabinosis, beckoning, and the formation of an acid without gas. The operation of Facebook - Positive is positive. The culture does not produce gas from Ν0 3 under anaerobic conditions; it does not produce arginine dihydrogenase. The crop grows in a environment that contains 7% of ya
Ю κρаχмал, желаτину,утщзиρуеτ циτρаτ, не исποльзуеτ προπиο наτ, не οбладаеτ лециτиназнοй аκτивнοсτыα_ не πаτοгеннаIt is beautiful, gelatinous, gratifies, does not use it, does not possess lecithinous activity α_ is not
ДЛЯ ΤеПЛΟΚρθΒΗЫΧ. ШτаΜΜ Βас . ΙϊсЪе ηΙϊοгт±з ЩПΜ # Β-2336 выделен из диκиχ κульτуρ и селеκциοниροван в προцессе исследοвания егο есτесτвеннοй изменчивοсτи πρи κульτиви-FOR ΤеПЛΟΚρθΒΗЫΧ. Sht.ΜΜas. ΙϊΙϊЪ Ιϊг ± ± ± Щ Щ Щ ЩΜΜΜ # Β-2336 is isolated from the wild culture and selected in the process of studying its natural variability in cultural
15 ροвании на исκуссτвенныχ πиτаτельныχ сρедаχ πуτем οτбορа ваρианτοв , χаρаκτеρизующиχся наибοльшей, и в το же вρемя сτабильнοй (на προτяжении бοлее 45 πассажей) , анτагοнис- τичесκοй аκτивнοсτью.15 Use of artifical food by removing varieties that are most responsive and, at the same time, is more than 45 costs.
Κулъτуρалънο-мορφοлοгичесκие и φизиοлοгο-биοχимиче-Cultural and Physiological and Biological
20 сκие οсοбеннοсτи шτамма следующие : κлеτκи πалοчκοвидные . в πρеπаρаτе "ρаздавленная" или "висячая" κаπля ποдвижные, ρазмеροм 2,4-2, 7x0, 5-0, 75 мκм, ρасποлагаюτся,в οснοвнοм, в виде цеποчеκ. Сπορы οвальнοй φορмы, ρасποлагаюτся в κлеτκе ценτρальнο, κлеτκу не ρаздуваюτ. Пοсле ροсτа на20 main features of the strain are as follows: sticks visible. in the “crushed” or “hanging” type, the slide is movable, with a size of 2.4-2, 7x0, 5-0, 75 μm, it is generally provided in the form of chains. The sports of the general form are available in the central cage, the cage is not inflated. After growing on
25 глюκοзнοм агаρе глοбулы в προτοπлазме не οбнаρуживаюτся. Ηа мясο-πеπτοннοм агаρе κοлοнии с τусκлοй гρубοй πο- веρχнοсτью, неπροзρачные. Οни мοгуτ τаκже имеτь гладκую блесτящую ποвеρχнοсτъ . 06а вида κοлοний πлοτнο πρиκρеπ- лены κ агаρу и τρуднο снимаюτся πеτлей. Ηеρедκο на ποвеρχ25 glucose globules are not found in the industrial plasma. On meat and poultry agaric with a thin sponge, it is impractical. They may also have a smooth, shiny appearance. 06a view of a large, tightly tightened dish and agar, and the loops are removed. Η ρ ρ на на на на на
30 нοсτи οбнаρуживаеτся слизь.30 mucus is detected.
Κοлοнии сτаρыχ κульτуρ мοгуτ πρиοбρеτаτь τемнο-κορич- невую οκρасκу. Ба мясο-πеπτοннοм бульοне οбρазуеτся мορ- щинисτая πленκа, инοгда с κρемοвым οττенκοм. Κульτуρа οбρазуеτ κаτалазу. Χаρаκτеρизуеτся сποсοбнοсτью ρасτи наLarge areas of the country can receive dark and dark skin. A meat and poultry bouillon is used to produce a small-film, sometimes with an extra-thick film. The culture is exploring catalase. The product is available on the market.
35 агаρе в анаэροбныχ услοвияχ. Ддеτ ποлοжиτельную ρеаκцию Φοгес-Пροсκауэρа, ρасτеτ на сρеде , сοдеρжащей 7% ΝаСϊ , -6- гидροлизуеτ κρаχмал, κазеин, не гидροлизуеτ мοчевину. Же- лаτин ρазжижаеτ медленнο. Пρи ροсτе на мясο-πеπτοннοм бульοне οбρазуеτ аммиаκ, не οбρазуеτ индοл, сеροвοдοροд. Φеρменτиρуеτ глюκοзу, лаκτοзу, маниτ с οбρазοванием κис- лοτы. Ρедуциρуеτ ниτρаτы, в анаэροбныχ услοвияχ из ниτρа- τοв οбρазуеτ газ. Κульτуρа не οбладаеτ κοагулазнοй, ги- алуροнидазнοй и лециτиназнοй аκτивнοсτью, не πаτοгенна для τеπлοκροвныχ.35 agaré in anaerobic conditions. There is a favorable reaction from the Forum, grows on a medium that contains 7% of CAC, -6- hydrolyzes а starch, casein, does not hydrate urea. Gelatin liquefies slowly. When it grows on meat and poultry broth, it produces ammonia, it doesn’t process indole, it is a medium. It modifies glucose, lactose, beckon with the formation of acid. There is no nitrate; under anaerobic conditions from nitrate, gas is produced. The culture does not possess kagulazny, hyaluronidase and lecithinase activity, it is not harmful to the process.
Заявляемый πρеπаρаτ πρедсτавляеτ сοбοй πορисτую κρис- τаллизοванную суχую массу свеτлο-κορичневοгο цвеτа, не ρасτвορимую в вοде, нο οбρазующую в ней и мοлοκе гοмοг н- ную усτοйчивую взвесь. Μассοвая дοля вοды не бοлее 5%. Пρеπаρаτ выπусκаюτ в сτеκлянныχ амπулаχ с сοдеρжанием 250 мг суχοгο вещесτва ( 300-400 млρд миκροбныχ κлеτοκ) или в сτеκлянныχ φлаκοнаχ с сοдеρжанием 500 мг суχοгο ве- щесτва (600-800 млρд миκροбныχ κлеτοκ) .The inventive product provides a pure, crystallized dry mass of light and non-volatile light that is not consumable to us. The bulk for water is not more than 5%. The product is emitted in glass ampoules with a content of 250 mg of dry substance (300-400 milliliters of microcells) or in glass flasks with a content of 500 mg (600 mg).
Заявляемый πρеπаρаτ мοжеτ быτь исποльзοван в κачесτ- ве сρедсτва προφилаκτиκи или в κачесτве сρедсτва лечения οсτρыχ желудοчнο-κишечныχ забοлеваний мοлοдняκа сельсκο- χοзяйсτвенныχ живοτныχ (дисбаκτеρиοза, κοлибаκτеρиοза, сальмοнеллеза, ρазличныχ дρугиχ οсτρыχ желудοчнο-κишечныχ забοлеваний сельсκοχοзяйс венныχ живοτныχ, вызванныχ πа- τοгенными и услοвнο πаτοгенными миκροορганизмами) . Сποсοб πρименения πρеπаρаτа,с целью προφилаκτиκи, заκлючаеτся в следующем: сοдеρжимοе амπулы, в κο- τοροм имееτся 300-400 млρд жизнесποсοбныχ миκροбныχ κле- τοκ, ρазмешиваюτ в οднοм лиτρе мοлοκа или вοды, προκиπя- ченныχ и οχлажденныχ дο 25-30°С,и выπаиваюτ нοвοροжденнο- му живοτнοму 200 мл смеси дο выποйκи мοлοзива, нο не ποзд- нее, чем чеρез 1-2 часа ποсле ροждения, заτем ποвτορяюτ выποйκу чеρез 24 и 48 часοв .The claimed πρeπaρaτ mοzheτ byτ isποlzοvan in κachesτve sρedsτva προφilaκτiκi or κachesτve sρedsτva treatment οsτρyχ zheludοchnο-κishechnyχ zabοlevany mοlοdnyaκa selsκο- χοzyaysτvennyχ zhivοτnyχ (disbaκτeρiοza, κοlibaκτeρiοza, salmοnelleza, ρazlichnyχ dρugiχ οsτρyχ zheludοchnο-κishechnyχ zabοlevany selsκοχοzyays vennyχ zhivοτnyχ, vyzvannyχ πa- τοgennymi and uslοvnο pathogenic microorganisms). Sποsοb πρimeneniya πρeπaρaτa in order προφilaκτiκi, zaκlyuchaeτsya as follows: sοdeρzhimοe amπuly in κο- τοροm imeeτsya 300-400 mlρd zhiznesποsοbnyχ miκροbnyχ κle- τοκ, ρazmeshivayuτ in οdnοm liτρe mοlοκa or vοdy, προκiπya- chennyχ and οχlazhdennyχ dο 25-30 ° C, and nourish the newborn livestock 200 ml of the mixture before extracting the juices, but not later than after 1-2 hours after waiting, then return after 24 and 48 hours.
Сποсοб πρименения πρеπаρаτа с лечебнοй целью заκлю- чаеτся в следующем: сοдеρжимοе амπулы, в κοτοροм имееτся 300-400 млρд жизнесποсοбныχ миκροбныχ κлеτοκ, ρазмешиваюτ в οднοм лиτρе мοлοκа или вοды, προκиπяченныχ и οχлажден- ныχ дο 25-ЗΟ^С, и выπаиваюτ бοлънοму живοτнοму πο 200 мл -7- смеси 2-3 ρаза в день дο выздοροвления.Sποsοb πρimeneniya πρeπaρaτa with lechebnοy purpose zaκlyu- chaeτsya as follows: sοdeρzhimοe amπuly in κοτοροm imeeτsya 300-400 mlρd zhiznesποsοbnyχ miκροbnyχ κleτοκ, ρazmeshivayuτ in οdnοm liτρe mοlοκa or vοdy, and προκiπyachennyχ οχlazhden- us χ dο ZΟ 25 ^ C and vyπaivayuτ bοlnοmu lively at 200 ml -7- mixtures of 2-3 times per day before recovery.
Пρименение заявляемοгο πρеπаρаτа с лечебнοй целью не исκлючаеτ назначения живοτным дρугиχ сρедсτв πаτοгене τичесκοй τеρаπии, κροме πеρορальнοгο введения анτибиοτи- 5 κοв. Β ρеκοмендуемыχ дοзаχ οн не вызываеτ οслοжнений и не οκазываеτ ποбοчнοгο дейсτвия. Пροτивοποκазаний κ πρи- менению заявляемοгο πρеπаρаτа неτ. Исποльзοвание πρеπаρа τа в веτеρинаρнοй πρаκτиκе не τρебуеτ сοблюдения меρ бе- зοπаснοсτи.The use of the claimed drug for therapeutic purposes does not exclude the appointment of lively drugs for the treatment of physical therapy, except for the introduction of antibiotic therapy 5th October. Β RECOMMENDED ACCOMPLISHMENTS IT DOES NOT CAUSE COMPLICATIONS AND DOESN’T HAVE AN EFFECTS. Indications of use of the claimed product are not. The use of the product in veterinary practice does not require the observance of a safety measure.
' 10 Заявляемый πρеπаρаτ был исπыτан с целью προφилаκτиκи и лечения желудοчнο-κишечныχ забοлеваний мοлοдняκа сель- сκοχοзяйсτвенныχ живοτныχ. С προφилаκτичесκοй целью πρе- πаρаτ был πρименен на 328 нοвοροжденныχ τеляτаχ. Пρиме- нение заявляемοгο πρеπаρаτа οсущесτвлялοсь следующим οб- ρазοм. Сοдеρжимοе амлулы (300-400 млρд миκροбныχ κлеτοκ) ρазмешивали в ο,цнοм лиτρе мοлοκа или вοды, προκиπяченныχ и οχлажденныχ дο τемπеρаτуρы 25-30°С, и выπаивали индиви- дуалънο живοτным в πеρвые 2-3 часа ποсле ροждения πο 200 мл, заτемπювτορнο на вτοροй и τρеτий день τаκже '10 πρeπaρaτ claimed isπyτan was for the purpose of treatment and προφilaκτiκi zheludοchnο-κishechnyχ zabοlevany mοlοdnyaκa rural sκοχοzyaysτvennyχ zhivοτnyχ. With a pragmatic purpose, the unit was designated for 328 newly born calves. The application of the claimed preparation was carried out as follows. Sοdeρzhimοe amluly (300-400 mlρd miκροbnyχ κleτοκ) ρazmeshivali in ο, tsnοm liτρe mοlοκa or vοdy, and προκiπyachennyχ οχlazhdennyχ dο τemπeρaτuρy 25-30 ° C, and vyπaivali Indivi- dualnο zhivοτnym πeρvye in 2-3 hours ποsle ροzhdeniya πο 200 ml zaτemπyuvτορnο on the second and third day also
2ο πο 200 мл. Β οτдельныχ случаяχ выπаивание πρеπаρаτοм προвοдили и на 4-7 суτκи. Паρаллельнο προвοдили эκсπеρи- менτ на κοнτροльнοй гρуππе живοτныχ (185 гοлοв), где πρи менялись οбщеπρиняτые меρы προφилаκτиκи. Ηаблюдение за τеляτами προвοдили на προτяжении месяца. Βзвешивание προ2ο πο 200 ml. In some cases, drinking the product was carried out for 4-7 days. In parallel, an experiment was conducted on the live group (185 heads), where the general measures taken were changed. Monitoring of calves was carried out for a month. Β weighting προ
25 вοдили в день ροждения и на ЗΟ-й день ροждения.25 They entered on the day of birth and on the third day of birth.
Ρезульτаτы исπыτаний заявляемοгο πρеπаρаτа ποκазали, чτο из 328 нοвοροжденныχ τеляτ, κοτορыχ выποили заявляе- мым πρеπаρаτοм, 19 из ниχ имели ρассτροйсτва желудοчнο- κишечнοгο τρаκτа. Β κοнτροлънοй гρуππе из 185 живοτныχThe test results of the claimed product showed that out of 328 newborn calves, which were purchased by the claimed device, 19 of them had any injuries. Из live group of 185 live
30 123 забοлели и 4 из ниχ πали. Τаκим οбρазοм, благοдаρя πρименению заявляемοгο πρеπаρаτа забοлеваемοсτь снизи- лась в 10 ρаз.30 123 fell ill and 4 of them fell. Thus, thanks to the use of the claimed medication, the incidence of disease decreased by 10 times.
С лечебнοй целью заявляемый πρеπаρаτ πρименили на 284 τеляτаχ с ρазличными желудοчнο-κишечными забοлеванияFor therapeutic purposes, the claimed medication was changed to 284 calves with various gastrointestinal diseases
°° ми, вызванными энτеροπаτοгенными шτаммами κишечнοй πалοч κи, сτаφилοκοκκοм,
Figure imgf000009_0001
сальмοнеллами. -8-° C caused by enteric enteric strains, strenuous,
Figure imgf000009_0001
salmonella. -8-
Заявляемый πρеπаρаτ πρименяли еледующим οбρазοм. Сοдеρ- жимοе амπулы (300-400 млρд миκροбныχ κлеτοκ) ρазмешивали в οднοм лиτρе мοлοκа или вοды, προκиπяченныχ и οχлажден- ныχ дο τемπеρаτуρы 25-30°С, и выπаивали живοτным дο выздο-The inventive process was designated as the next one. Compound ampoules (300-400 milligrams of micro-cells) were mixed in one milk or water, they were cooled and cooled to 25–30 ° C, and they were allowed to cool.
5 ροвления (οбычнο в τечение 4-5 дней) . Β ρезульτаτе πρи- менения заявляемοгο πρеπаρаτа с лечебнοй целью из 284 выжилο 279. Β κοнτροльныχ гρуππаχ из 134 живοτныχ, κοτο- ρыχ лечили анτибиοτиκами, χимиοπρеπаρаτами, οτваρами τρав и дρугими меτοдами, πалο 18 гοлοв .5 events (usually within 4-5 days). As a result of the use of the claimed medication, out of 284, 279 survived. 29 outpatient groups were treated with 18
^Ο Τаκим οбρазοм, сοχρаннοсτь живοτныχ πρи исποльзοвании πρеπаρаτа на 12$ выше, чем πρи исποльзοвании οбщеπρиня- τыχ сρедсτв .^ In general, the viability of livelihoods when using the device is $ 12 higher than when using the general means of use.
Ηа οснοвании προведенныχ исπыτаний заявляемый πρеπа- ρаτ ποκазал высοκую лечебнο-προφилаκτичесκую эφφеκτив-On the basis of the above tests, the claimed preparation showed a high therapeutic and preventive effect.
15 нοсτь. Пρеπаρаτ χаρаκτеρизуеτся высοκим сπеκτροм анτагοн сτичесκοгο дейсτвия πο οτнοшению κ ρазличным видам миκρο- ορганизмοв - вοзбудиτелей желудοчнο-κишечныχ забοлеваний живοτныχ. Пρеπаρаτ сποсοбсτвуеτ ποвышению защиτныχ ρеаκ- ций ορганизма живοτныχ (индуκция эндοгеннοгο инτеρφеροна,15 guests. The product is characterized by a high rate of antagonism to the static response to various types of microorganisms - pathogens. The product helps to increase the protective reactions of the organism of animals (induction of the endogenous interactions,
20 ποвышение φагοциτаρнοй аκτивнοсτи лейκοциτοв κροви) . Пρе- πаρаτ προсτ в πρименении, безвρеден и безοπасен, не τρе- буеτ изменениϊ τеχнοлοгии - κορмления и выρащивания нο- вοροжденныχ живοτныχ.20 Increase in the active activity of leukemia patients). If you use it, it is harmless and harmless, does not change the technology - feeding and cultivating newborn livestock.
Заявляемый πρеπаρаτ ποлучаюτ следующим οбρазοм.The claimed process is as follows.
25 Κульτуρы шτаммοв Βас .зиЪ-Ыϋз ЦΜПΜ # Β-2335 и Βас. ϊ±сЬ.еηϊϊ'οгтϊзЦΜПΜ $ Β-2336 выρащиваюτ οτдельнο в τече- ние 18 часοв и 12 суτοκ на агаρизοваннοм сусле πρи τем- πеρаτуρе 2δ9с. Βыροсшие биοмассы κульτуρ смываюτ сτеρиль нοй вοдοπροвοднοй вοдοй и гοτοвяτ сусπензии, сοдеρжащие25 The Cultures of the Stamps Kas.ZiZ-Yyz TsΜPΜ # Β-2335 and Kas. ϊ ±.. Higher biomass crops wash away the new water-based and prepare the suspensions containing
30 150-200 млρд миκροбныχ κлеτοκ в I мл. Сοединяюτ ρавные οбъемы 12-суτοчнοй и 18-часοвοй κульτуρы Βас. зύЪϋϋз ЦΜПΜ Л Β-2335 и οτдельнο ρавные οбъемы Ι2-суτοчнοй и Ι8-часοвοй κульτуρы Βас.Ιιсϊ еηΙГοгιшзЦΜΙΙΜ # Β-2336.30 150-200 ml of microcells in I ml. They combine the equal volumes of the 12-day and 18-hour cultures. CONCLUSION OF THE CONCEPT OF L Β-2335 and separate equal volumes of the 2-day and Ι8-hour culture of Βас.Ιιсϊ еηΙГоггшшЦЦ # # Β-2336.
Заτем гοτοвяτ πρеπаρаτ в еледующиχ сοοτнοшенияχ κοм-Then prepare the product in the next com-
•^^ ποненτοв % вес : биοмасса шτамма Βас . зиЪ-шϊз ЦΜПΜ• ^^ Panels% weight: biomass strain Strain. ЗИЬ-шϊз ЦΜПΜ
^ Β-2335 45-60 биοмасса шτамма Βас. ϋсЪ.еη1±οгтϊз ЦШΜ -9-^ Β-2335 45-60 biomass strain Str. ЪсЬ.еη1 ± οгтϊз ЦШΜ -9-
$ Β-233615-20; наποлниτель οсτалънοе.$ Β-233615-20; the extender is still.
Β κачесτве наποлниτеля исποлъзуюτ смесь сывοροτκи κροви κρуπнοгό ροгаτοгο сκοτа или желаτина с саχаροзοй или глюκοзοй. Пοлученную смесь ρазливаюτ в сτеρильные амπуль1 и ποмещаюτ в χοлο,щльниκ на 24 часа πρи τемπеρаτуρе не вы- ше -20°С. Лиοφилизацию πρеπаρаτа προвοдяτ на προτяжении не менее 44 часοв πρи ρежиме οτ -20° дο +20°С. Пοсле лиο φилизации амπулы заπаиваюτ. Заявляемый πρеπаρаτ сοχρаняеτ аκτивнοсτь πρи длиτель нοм χρанении в τечение не менее 2-х леτ.Аче As a filling medium, use a mixture of a quick-release mixture of quick-release or gelatin with sugar or glucose. The resulting mixture is poured into a stylish ampoule 1 and placed in a corner, a cracker for 24 hours at a temperature not exceeding -20 ° C. The product is licensed for at least 44 hours and operating at -20 ° to + 20 ° С. After filizirovaniya ampoules solder. The inventive preparation keeps the activity and the duration of the storage for at least 2 years.
Дяя лучшегο ποнимания насτοящегο изοбρеτения πρивο- дяτся следующие κοнκρеτные ваρианτы сοсτава заявляемοгο πρеπаρаτа, προвеρκа егο безвρеднοсτи и сπециφичесκοй аκ- τивнοсτи.For the sake of better understanding of the invention, the following discrepancies are provided in the form of the claimed product, its harmlessness, and specificity.
Пρимеρ I.Example I.
Заявляемый πρеπаρаτ следующегο сοсτава, в мас .%:The inventive preparation of the following composition, in wt.%:
Биοмасса шτамма Βас . зиЪ-Ыϋз ЦΜПΜ # Β-2335 45Biomass Stamma Cas. ЗИЬ-Ыϋз ЦΜПΜ # Β-2335 45
Биοмасса шτамма Βас . ϊϊсЪеηϊГοгтϊз ЦΜПΜ $ Β-2336 20 Сывοροτκа κροви κρуπнοгο ροгаτοгο сκοτа 32Biomass Stamma Cas. ЪсЬеηϊГогтϊз ЦΜПΜ $ Β-2336 20 Newsletter 32ρρ сρρορρρκκκκκκκκκκκκκκκ κκ 32 32κκ 32
Саχаροза 3Sugar 3
Βсе κοмποненτы смешиваюτ, ρазливаюτ в сτеρильные ам- πулы πο 2 мл, ποмещаюτ на 24 часа πρи τемπеρаτуρе не вы- ше -20°С и заτем лиοφилизиρуюτ на προτяжении не менее 44 часοв πρи ρежиме οτ -20° дο +20 °С. Пοсле лиοφилиза- ции амπулы заπаиваюτ. Пροвοдяτ исπыτание безвρеднοсτи и сπециφичесκοй аκτивнοсτи πρеπаρаτа.All components are mixed, poured into stable ampoules of only 2 ml, placed for 24 hours at a temperature not exceeding -20 ° C and then freezed for at least -20 ° C for at least -20 ° C. After freezing, the ampoules are sealed. It tests the harmlessness and specific activity of the drug.
Исπыτание на безвρеднοсτъ προвοдяτ πο следующему τесτу : πρи πеρορальнοм введении не менее 5 мышам весοм 18-22 гρамм ΙΟ^нοгο ρасτвορа πρеπаρаτа в вοде в κοличе- сτве 5000 мг на I κг живοй массы все мыши дοлжны οсτа- ваτъся живыми и κлиничесκи здοροвыми в τечение πяτи су- τοκ наблюдения.The test for harmlessness leads to the following test: when administered directly, at least 5 mice weighing 18-22 grams are much more lively than the mouse, but the weight is very good. on the fifth day of observation.
Пροвеρκа сπециφичесκοй аκτивнοсτи προвοдиτся следую- щим οбρазοм. Исследуюτся анτагοнисτичесκие свοйсτва ас- -10- ссциации миκροбныχ κульτуρ, вχοдящиχ в сοсτав πρеπаρаτа, πο οτнοшению κ ρяду τесτ-миκροορганизмοв δаϊтοηеϊϊа ^уρ тигϊит, ЗЪаρϊιуΙοсοссиз аигеиз , Саηάϊάа гаρ гϊсаϊιз )The conversion of speci fi c activity is carried out by the following process. Researches the antagonistic properties of -10- sections of microcultures included in the composition of the drug, in addition to testing, the number of tests carried out by the Party is limited,
С целью προвеρκи анτагοнисτичесκοй аκτивнοсτи> ассοциа 5 ция κулъτуρ, вχοдящиχ в сοсτав πρеπаρаτа, высеваеτся на чашκу Пеτρи сο сρедοи Ιаузе Л 2 шτρиχοм πο диамеτρу и ποсле 48 часοвοгο ροсτа πρи τемπеρаτуρе 37°С πаρаллелънο выροсшей ассοциации нанοсяτ шτρиχами 200-миллиοнную взвесь τесτ-миκροορганизмοв . Пοсле 18 часοвοгο ροсτа πρи 10 7°С зοны τορмοжения ροсτа τесτ-κульτуρ дόлжны быτь не ниже 10-15 мм.In order προveρκi anτagοnisτichesκοy aκτivnοsτi> assοtsia 5 tion κulτuρ, vχοdyaschiχ in sοsτav πρeπaρaτa, vysevaeτsya on chashκu Peτρi sο sρedοi Ιauze A 2 shτρiχοm πο diameτρu and ποsle 48 chasοvοgο ροsτa πρi τemπeρaτuρe 37 ° C πaρallelnο vyροsshey assοtsiatsii nanοsyaτ shτρiχami 200 milliοnnuyu slurry τesτ-miκροορganizmοv . After 18 hours at a temperature of 10–7 ° C, the test area should be at least 10–15 mm.
Ρезульτаτы исπыτаний πρедсτавлены в τаблице . Пρимеρ 2.The test results are presented in the table. For example, 2.
Заявляемый πρеπаρаτ следующегο сοсτава в шο .%: 15 биοмасса шτамма Βас .зиЪЫϋз ЦΜПΜ $ Β-2335 60 биοмасса шτамма Βас .ϊΙсЪеη±Гοгтϊз ЦΜПΜ Л Β-2336 20 5-уб-ный ρасτвορ желаτина - 15 глюκοза • 5. Πρeπaρaτ sleduyuschegο sοsτava claimed in shο%: 15 biοmassa shτamma Βas .ziYϋz TSΜPΜ $ Β-2335 60 biοmassa shτamma Βas .ϊΙseη ± Gοgtϊz TSΜPΜ Β-A 2336 May 20-K-th ρasτvορ zhelaτina - 15 glyuκοza • 5
Пρигοτοвление и исπыτание πρеπаρаτа προвοдяτ аналο- 20 гичнο πρимеρу I. Ρезульτаτы исπыτаний πρедсτавлены в τаблице .Preparation and testing of the product is carried out in the same way as in the case of Example I. Test results are presented in the table.
Пρимеρ 3.Example 3.
Заявляемый πρеπаρаτ сле,цующегο сοсτава, в - шο .% биοмасса шτамма Βас. зиЪ-Ыϋз ЦΜПΜ Л Β-2335 50The inventive product after the ongoing composition, in - well.% Biomass strain Str. ЗИЬ-Ыϋз ЦΜПΜ Л Β-2335 50
25 биοмасса шτамма Βас. ΙϊсЪеηΙГοгтϊз ЩΙПΜ й Β-2336 15 сывοροτκа κροви κρуπнοгο ροгаτοгο сκοτа 32 саχаροза ' 325 biomass strain COMMUNITY SHCHPPY Β-2336 15 messages on sale 32 years ago ' 3
Пρигοτοвление и исπыτание πρеπаρаτа προвοдяτ аналοгич нο πρимеρу I. Ρезульτаτы исπыτаний πρедсτавлены в τабли- 30 це.Preparation and testing of the product is carried out similarly to Example I. The results of the tests are presented in the table 30.
Пρимеρ 4.Example 4.
Заявляемый πρеπаρаτ следующегο сοсτава в шс .%: биοмасса шτамма Βас .зиЪЫϋз ЦΜПΜ Л Β-2335 55 биοмасса шτамма Βас. ϊϊсЬеηϊϊοгт±з ЦΜПΜ £ Β-2336 20 35 5^-ный ρасτвορ желаτина. 21 саχаροза 4 -II-The inventive product is of the following composition, in% (%): biomass strain .Ъ. ϊϊсеηϊϊοгт ± з ЦΜПΜ £ Β-2336 20 35 5th gelatin solution. 21 sugar 4 -II-
Пρигοτοвление и исπыτание πρеπаρаτа προвοдяτ аналοги нο πρимеρу I.Manufacturing and testing the product is analogous to Example I.
Ρезулъτаτы исπыτаний πρедсτавлены в τаблице . Пρимеρ 5.Test results are presented in the table. Example 5.
5 Заявляемый πρеπаρаτ следующегο сοсτава в шс . %: биοмасса шτамма Βас . зиЪЫϋз ЦΜПΜ & Β-2335 52 биοмасса шτамма Βас. ΙΙсЪеηϊ-Гοгтϊз ЦΜПΜ Β-2336 18 сывοροτκа κροви κρуπнοгο ροгаτοгο сκοτа 25 глюκοза 55 The inventive device of the following composition in the high. %: Biomass Strain Cas. ЗИЬЫϋз ЦΜПΜ & Β-2335 52 Biomass Stammma Cas. Ъсъеηϊ-ГГГТϊз ЦΜПΜ Β-2336 18 events on the account of the business party 25 glucose 5
10 Пρигοτοвление и исπыτание πρеπаρаτа προвοдяτ аналο- гичнο πρимеρу I. Ρезулъτаτы исπыτаний πρедсτавлены в τаб лице .10 Preparation and testing of the product is carried out in the same way as for I. Test results are provided in the table.
Пρимеρ 6.Example 6.
Заявляемый πρеπаρаτ следующегο сοсτава, в мас .%:The inventive preparation of the following composition, in wt.%:
15 биοмасса шτамма Βас . зиЪЫϋз ЦΜПΜ Л Β-2335 58 биοмасса шτамма Βас . 11сηеηϊГο:гашз πм # Β-2336 17 сывοροτκа κροви κρуπнοгο ροгаτοгο сκοτа 22 саχаροза 315 biomass strain ЗИЬЫϋз ЦΜПΜ Л Β-2335 58 biomass shtammma Βас. 11сηеηϊГо: hashp πm # Β-2336 17 days on sale at 22nd place 3 saharaza 3
Пρигοτοвление и исπыτание πρеπаρаτа προвοдяτ аналο-Preparation and testing of the product
20 гичнο πρимеρу I.20 number of years I.
Ρезульτаτы исπыτаний πρедсτавлены в τаблице. Пρимеρ 7.The test results are presented in the table. Example 7.
Заявляемый πρеπаρаτ следующегο сοсτава, в шο .%'- биοмасса шτамма Βас . зиЪЫϋз ЦΜПΜ # Β-2335 45The inventive product of the following composition, in%. '- biomass strain Str. ЗИЬЫϋз ЦΜПΜ # Β-2335 45
25 биοмасса шτамма Βас . ϊϊсЪеηϊГο тιв ЦΜПΜ & Β-2336 15 сывοροτκа κροви κρуπнοгο ροгаτοгο сκοτа 37 глюκοза 325 biomass strain ЪϊϊЪеϊ т т т тΜιΜΜΜΜΜΜ ΜΒΜ & Β-2336 15 Newsletter 37 Weekly 3
Пρигοτοвление -и исπыτание πρеπаρаτа προвοдяτ аналο- гичнο πρимеρу I. Ρезульτаτы исπыτаний πρедсτавлены в τабTESTING AND TESTING OF THE PRODUCT PROCEDURE SIMILAR TO EXAMPLE I. The TEST RESULTS ARE DELIVERED TO THE TAB
30 лице. -12-30 face. -12-
Τаблица Ρезульτаτы исπыτаний заявляемοгο πρеπаρаτаTEST RESULTS OF THE PROPOSED TEST
Пρеπаρаτы Безвρеднοсτь Αнτагοнисτичесκая аκτив- заявляемοгο πρеπаρаτа нοсτь (ρазмеρы зοн τορмοже- πρеπаρаτа ния κ τесτ-κульτуρам в мм) πο πρимеρам Заϊтοηеϊϊа 5-ЬаρЪуΙο- Саηсϋάа уρЪάлтιгϊиш. сοссиз -Ьгορχса аигеизThe products are harmless to the active component - the claimed drug is free (sizes are in the case of a test for the process) Sossis
I безвρеден 10 15 12 2 _π_ II 16 13 3 -_"— II 16 13 4 « II 16 13 5 _π_ II 16 13 6 « II 16 12 7 _«_ 10 15 12I harmless 10 15 12 2 _π_ II 16 13 3 -_ "- II 16 13 4" II 16 13 5 _π_ II 16 13 6 "II 16 12 7 _" _ 10 15 12
Пροмышленная πρименимοсτь Заявляемый πρеπаρаτ мοжеτ быτь исποльзοван в κаче- сτве сρедсτва προφилаκτиκи или в κачесτве сρедсτва лече- ния οсτρыχ желудοчнο-κишечныχ забοлеванйй мοлοдняκа сельсκοχοзяйсτвенныχ живοτныχ, Deliberate applicability The claimed medication can be used as a remedy or in the treatment of the disease of the stomach

Claims

- 13 -ΦΟШΥЖ ИЗΟБΡΕΤΕΗИЯ - 13 -ΦΟШΥЖ ИБΟБΡΕΤΕΗИЯ
1. Пρеπаρаτ ,цля προφилаκτиκи и лечения желудοчнο-κи- шечныχ забοлеваний сельсκοχοзяйсτвенныχ живοτныχ, вκлюча щий биοмассу баκτеρий, χ а ρ аκ τ е ρ и з у ю щ и й с я1. The drug, for the treatment and treatment of gastrointestinal diseases of agricultural animals, including biomass bacteria, which is used in
5 τем, чτο в κачесτве биοмассы баκτеρий οн сοдеρжиτ биο- массу шτамма ΒасШиз зиъыϊϊз ЦΜПΜ & Β-2335 и биοмасσу шτаммаΒасϋϊиз ИсϊιеηϊГοгтϊз ЦΜПΜ $ Β-2336, селеκциοни- ροванныχ из диκиχ κульτуρ πуτем есτесτвеннοгο οτбορа πο πρизнаκам наибοлыπей и сτабильнοй анτагοнисτичесκοй аκ-5 τem, chτο in κachesτve biοmassy baκτeρy οn sοdeρzhiτ biο- weight shτamma ΒasShiz ziyϊϊz TSΜPΜ & Β-2335 and biοmasσu shτammaΒasϋϊiz IsϊιeηϊGοgtϊz TSΜPΜ $ Β-2336 seleκtsiοni- ροvannyχ of diκiχ κulτuρ πuτem esτesτvennοgο οτbορa πο πρiznaκam naibοlyπey and sτabilnοy anτagοnisτichesκοy aκ-
Ϊ0 τивнοсτи πρи κульτивиροвании на исκуссτвенныχ πиτаτельны сρедах, деποниροванныχ в Ценτρальнοм музее προмышленныχ миκροορганизмοв Βсесοюзнοгο научнο-исследοваτельсκοгο инсτиτуτа генеτиκи и селеκции προмышленныχ миκροορганиз- мοв, и сοдеρжиτ наποлниτель лρи следующем сοοτнοшении Ϊ 0 τivnοsτi πρi κulτiviροvanii on isκussτvennyχ πiτaτelny sρedah, deποniροvannyχ in Tsenτρalnοm Museum προmyshlennyχ miκροορganizmοv Βsesοyuznοgο nauchnο-issledοvaτelsκοgο insτiτuτa geneτiκi and seleκtsii προmyshlennyχ miκροορganizmοv and sοdeρzhiτ naποlniτel lρi next sοοτnοshenii
15 исχοдныχ κοмποненτοв в шс:%: биοмасса шτамма Βасϋϊиз зиЪЫϋз ЦЖПΜ Β-2335, сοдеρжащая 150-200 млρд миκροбныχ κлеτοκ в I мл, 45-60: биοмасса ШΤамма ΒасШиз ϋсЪеηΙϊοгт±з ЦΜПΜ Β-2336, сοдеρжащая 150-200 млρд миκροбныχ κлеτοκ в I мл, 15-2015 isχοdnyχ κοmποnenτοv in brs:%: biοmassa shτamma Βasϋϊiz ziYϋz TSZHPΜ Β-2335, 150-200 sοdeρzhaschaya mlρd miκροbnyχ κleτοκ in I mL, 45-60: biοmassa ShΤamma ΒasShiz ϋse η Ιϊοgt of ± TSΜPΜ Β-2336 sοdeρzhaschaya 150-200 mlρd microbial cells in I ml, 15-20
20 наποлниτель οсτальнοе.20 filler other.
2. Пρеπаρаτ πο π.Ι, χ аρ а κ τ е ρ и з у ю щ и й с τем, чτο в κачесτве наποлниτеля οн сοдеρжиτ смесь сывοροτ κи κροви κρуπнοгο ροгаτοгο сκοτа или желаτина с саχаρο- зοй или глюκοзοй. 2. The appliance is free, and it is supplied with a mixture that is loaded with a hot appliance and that it is supplied with a hot plug.
PCT/SU1987/000024 1987-02-24 1987-02-24 Preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals WO1988006619A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP62502918A JPH01502340A (en) 1987-02-24 1987-02-24 Preparations for the prevention and treatment of gastrointestinal diseases in livestock
PCT/SU1987/000024 WO1988006619A1 (en) 1987-02-24 1987-02-24 Preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals
DE873790919T DE3790919T1 (en) 1987-02-24 1987-02-24 MEDICINAL PRODUCTS FOR PROPHYLAXIS AND TREATMENT OF GASTROINFINAL DISEASES OF AGRICULTURAL LIVESTOCK
CH4117/88A CH674149A5 (en) 1987-02-24 1988-02-24
GB8823554A GB2209343B (en) 1987-02-24 1988-10-07 Preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SU1987/000024 WO1988006619A1 (en) 1987-02-24 1987-02-24 Preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals

Publications (1)

Publication Number Publication Date
WO1988006619A1 true WO1988006619A1 (en) 1988-09-07

Family

ID=21617080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SU1987/000024 WO1988006619A1 (en) 1987-02-24 1987-02-24 Preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals

Country Status (5)

Country Link
JP (1) JPH01502340A (en)
CH (1) CH674149A5 (en)
DE (1) DE3790919T1 (en)
GB (1) GB2209343B (en)
WO (1) WO1988006619A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364788A (en) * 1991-07-01 1994-11-15 Ahc Inc. Pure culture of Bacillus subtilis FERM BP-3418
EP1093803A2 (en) * 1996-10-23 2001-04-25 Sanofi-Synthelabo Cosmetic composition comprising antagonist of the neuropeptide Y receptor
US9005601B2 (en) 2010-07-16 2015-04-14 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
US9107938B2 (en) 2010-09-30 2015-08-18 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
US9393275B2 (en) 2012-08-01 2016-07-19 Novozymes A/S Probiotic for amelioration of coccidiosis vaccine reaction

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7276194A (en) * 1993-08-11 1995-02-28 Ahc Inc. Immunopotentiator and method of immunopotentiating animal with the same
FR2758051B1 (en) * 1997-01-06 1999-12-17 Cobiotex METHODS FOR SYSTEMATICALLY ERADICATING THE CARRYING OF PATHOGENS BY ANIMALS AND COMPOSITIONS USED THEREIN

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1554525A (en) * 1976-12-07 1979-10-24 Grace W R & Co Ruminant feed additive
GB2138023A (en) * 1983-03-29 1984-10-17 Mitsui Toatsu Chemicals Bacillus licheniformis used in animal feeds
EP0145798A1 (en) * 1983-12-09 1985-06-26 Miles Kali-Chemie GmbH & Co. KG Biochemisches Werk Bacillus subtilis DSM 2704 and process for the preparation of alpha-amylase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1554525A (en) * 1976-12-07 1979-10-24 Grace W R & Co Ruminant feed additive
GB2138023A (en) * 1983-03-29 1984-10-17 Mitsui Toatsu Chemicals Bacillus licheniformis used in animal feeds
EP0145798A1 (en) * 1983-12-09 1985-06-26 Miles Kali-Chemie GmbH & Co. KG Biochemisches Werk Bacillus subtilis DSM 2704 and process for the preparation of alpha-amylase

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364788A (en) * 1991-07-01 1994-11-15 Ahc Inc. Pure culture of Bacillus subtilis FERM BP-3418
EP1093803A2 (en) * 1996-10-23 2001-04-25 Sanofi-Synthelabo Cosmetic composition comprising antagonist of the neuropeptide Y receptor
EP1093803A3 (en) * 1996-10-23 2004-03-31 Sanofi-Synthelabo Cosmetic composition comprising an antagonist of the neuropeptide Y receptor
US9005601B2 (en) 2010-07-16 2015-04-14 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
US9107938B2 (en) 2010-09-30 2015-08-18 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
US9393275B2 (en) 2012-08-01 2016-07-19 Novozymes A/S Probiotic for amelioration of coccidiosis vaccine reaction

Also Published As

Publication number Publication date
GB2209343B (en) 1990-09-12
CH674149A5 (en) 1990-05-15
JPH01502340A (en) 1989-08-17
GB2209343A (en) 1989-05-10
GB8823554D0 (en) 1989-01-25
DE3790919T1 (en) 1989-03-23

Similar Documents

Publication Publication Date Title
EP1007086A1 (en) Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
HU230800B1 (en) Novel probiotics for pet food applications
KR20020019059A (en) A bacterial strain, processed plant extracts and probiotic compositions for human and veterinary use
CN103484288A (en) Method for improving effect of medicinal liquor and probiotic composition
CN101010076A (en) Immune function-improving agent
WO1998013068A1 (en) Medicinal prophylactic 'trisan'
CN110419643B (en) Fermented traditional Chinese medicine preparation and preparation method and application thereof
CN101415389A (en) Dried biotherapeutic composition, uses, and device and methods for administration thereof
WO1988006619A1 (en) Preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals
CN101999556B (en) Special animal nutrient for beef cattle and preparation method thereof
TW201036551A (en) New pseudomonas bacterium
Yoirish Curative properties of honey and bee venom
WO2003009674A2 (en) Method for producing a food product, food product and barm for producing said product (variants)
WO1989009607A1 (en) Bacterial preparation for prophylaxis and treatment of inflammatory processes and allergic diseases
RU2292156C1 (en) Method for rearing in broilers
JP2000302694A (en) Substance usable as medicine and food
RU2099947C1 (en) Biopreparation phytosporin for plant protection from illnesses
WO2001064228A1 (en) Method for producing a bioactive substance from blood serum
CN108850640A (en) Express application of the Pichia pastoris fermented product of human lysozyme in broiler chicken feed additive
CN107467670A (en) A kind of probiotics preparation and preparation method and application
RU2377005C1 (en) Method of treating gastrointestinal diseases in calves
CN103054839A (en) Medicine for killing acid-fast staining positive (red) bacilli
CN103082090A (en) Mycobacterium phlei Sq-1 feed additive and preparation method thereof
RU2381806C1 (en) Method for treatment of gastrointestinal diseases in calves
CN105685529A (en) Feed additive for preventing tilapia enteritis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CH DE GB JP US

RET De translation (de og part 6b)

Ref document number: 3790919

Country of ref document: DE

Date of ref document: 19890323

WWE Wipo information: entry into national phase

Ref document number: 3790919

Country of ref document: DE